Stocks
Peloton’s performance: Earnings gears and future frontiers | Entrepreneur
Peloton Interactive Inc. (NASDAQ: PTON) recently released its fiscal Q2 2024 earnings, presenting a mixed picture that has garnered attention from investors in the consumer discretionary sector. The company, known for...
Google in 2024: A roller coaster ride through Silicon Valley | Entrepreneur
Alphabet Inc. (NASDAQ: GOOG), the corporate parent of Google, demonstrated remarkable financial strength in the rapidly changing and volatile tech sector. Google's Q4 2023 earnings were particularly significant for the company, showcasing...
3 outperforming alternatives to the VWO emerging markets ETF | Entrepreneur
In the U.S. equity space, it's the SPDR S&P 500 ETF (commonly known as SPY). In international equities, it's the Vanguard FTSE Developed Markets Index Fund (VEA). For domestic...
3 Biotech Stock Sensations to Snatch up This Week | Entrepreneur
The future of the biotech industry appears promising, fueled by technology-driven advancements, increasing merger and acquisition maneuvers, and developing product pipelines. Given this backdrop, quality biotech stocks BioNTech SE...
Walmart rewrites the rulebook: Equity, expansion, and evolution | Entrepreneur
Walmart (NYSE: WMT) has recently unveiled a series of strategic initiatives that underscore its commitment to growth, employee empowerment, and customer satisfaction. These announcements, ranging from a significant stock...
How to Understand Limiting vs. Productive Attitudes Among Day Traders | Entrepreneur
Opinions expressed by Entrepreneur contributors are their own. The requirements for day traders are straightforward:You need knowledge of the profession. There's indeed a lot to learn, but it's not...
5,000 or Bust! is New Stock Market Slogan | Entrepreneur
The S&P 500 (SPY) is adding to the gains from 2023 early in the new year. However, not every group is participating. In fact, small and mid caps are...
4 Biotech Stocks With Massive Buy Potential | Entrepreneur
The biotech sector is poised for robust long-term growth, driven by significant developments in drug approvals, innovative therapies, and government-backed initiatives. Hence, investors might consider buying fundamentally solid biotech...
